We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
-2.01%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$2.27M
Cap. Flow
+$5.33M
Cap. Flow %
4.9%
Top 10 Hldgs %
89.62%
Holding
33
New
2
Increased
7
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$9.04M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$8.72M
3
TECX
Tectonic Therapeutic
TECX
+$5.52M
4
CLYM
Climb Bio
CLYM
+$968K
5
VTGN icon
VistaGen Therapeutics
VTGN
+$444K

Top Sells

Rank Stock Value
1
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
+$6.86M
2
ANF icon
Abercrombie & Fitch
ANF
+$4.43M
3
ADVM
Adverum Biotechnologies
ADVM
+$2.23M
4
QNCX icon
Quince Therapeutics
QNCX
+$2.12M
5
TLYS icon
Tilly's
TLYS
+$1.34M

Sector Composition

Rank Sector Weight
1 Healthcare 55.73%
2 Technology 2.04%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRZN icon
26
Surrozen
SRZN
$214M
$43.7K 0.04%
5,951
-91,321
-94% -$868K
ANF icon
27
Abercrombie & Fitch
ANF
$4.55B
– –
-117,500
Closed -$4.43M
IVVD icon
28
Invivyd
IVVD
$166M
– –
-134,696
Closed -$141K
LITS
29
Lite Strategy Inc
LITS
$33.1M
– –
-22,966
Closed -$151K
QNCX icon
30
Quince Therapeutics
QNCX
$21.3M
– –
-7,059
Closed -$2.12M
TLYS icon
31
Tilly's
TLYS
$114M
– –
-190,518
Closed -$1.34M
LENZ
32
LENZ Therapeutics
LENZ
$178M
– –
-21,756
Closed -$396K
PRDS
33
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-3,791,633
Closed -$6.86M
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return
PMSA
Patrick M. Sweeney & Associates Libertyville, Illinois $156M AUM 19.16% 1-Year Est. Return
GSWA
Good Steward Wealth Advisors Clarksville, Tennessee $156M AUM 13.06% 1-Year Est. Return
SPM
Summit Portfolio Management Las Vegas, Nevada $155M AUM

BML Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, BML Capital Management held 33 positions worth $109M, down 2% from $111M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

BML Capital Management deployed $5.33M of net new capital in Q3 2023, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was VistaGen Therapeutics: 100,000 shares worth $524K.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Adverum Biotechnologies, an estimated $2.23M trimmed.

  • BML Capital Management's largest Q3 2023 buy was VistaGen Therapeutics: 100,000 shares worth $524K.
  • BML Capital Management added most to iShares 0-3 Month Treasury Bond ETF in Q3 2023, an estimated $9.04M increase.
  • BML Capital Management's biggest Q3 2023 reduction was Adverum Biotechnologies, cutting an estimated $2.23M.
  • BML Capital Management fully exited Pardes Biosciences, Inc. Common Stock in Q3 2023, selling an estimated $6.86M.
  • BML Capital Management's ten largest holdings make up 90% of its $109M portfolio in Q3 2023.
  • BML Capital Management opened 2 new positions and closed 7 in Q3 2023.
  • BML Capital Management's portfolio value fell 2% quarter-over-quarter to $109M.

Based on BML Capital Management's 13F filing for Q3 2023, filed 23 Oct 2023.